Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to transforming the treatment landscape for patients with serious bleeding and thrombotic disorders. The company leverages its deep expertise in blood clotting biology to develop a pipeline of first-in-class prophylactic therapies. Hemab's strategic focus is on addressing rare and underserved hematological conditions where current treatment options are limited or non-existent. The company's lead product candidate, HMB-001, is a bispecific antibody designed to bind and recruit Factor VIIa to activated platelets, specifically targeting Glanzmann Thrombasthenia, a severe rare bleeding disorder. Another key candidate in their pipeline is HMB-VWF, aimed at treating von Willebrand disease. By utilizing innovative engineering platforms, Hemab aims to provide long-acting, subcutaneous treatments that improve patient outcomes and quality of life. Founded by experts in the field of hematology and backed by prominent life science investors, Hemab operates with a dual presence in Denmark and the United States. The company is led by CEO Benny Sorensen, MD, PhD, who brings extensive experience in clinical development and hematology. Hemab's mission is to build a sustainable, fully integrated company that delivers life-changing medicines to patients globally, while advancing the science of hemostasis and thrombosis.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
...and much more!